Sarepta Therapeutics Inc (SRPT)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | -498,088 | -636,715 | -355,423 | -493,118 | -683,211 |
| Long-term debt | US$ in thousands | 1,132,520 | 1,544,290 | 1,096,880 | 992,493 | 681,900 |
| Total stockholders’ equity | US$ in thousands | 859,337 | 384,950 | 928,009 | 761,759 | 818,187 |
| Return on total capital | -25.01% | -33.00% | -17.55% | -28.11% | -45.54% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $-498,088K ÷ ($1,132,520K + $859,337K)
= -25.01%
Sarepta Therapeutics Inc's return on total capital has shown fluctuations over the past five years. The company's return on total capital was -25.01% in 2023, improving from -33.00% in 2022 but still reflecting a negative return. However, this return was better than the -45.54% reported in 2019. The company's return on total capital has been negative in all the years analyzed, indicating that Sarepta Therapeutics Inc has not been effectively generating returns on its total capital employed. Further analysis of the company's operations and financial management may be required to understand the reasons behind these negative returns and to identify potential areas for improvement.
Peer comparison
Dec 31, 2023